News Releases

News & Resources

News Releases

Synteract to Share Insights on Clinical Trials in Orphan Indications at Outsourcing in Clinical Trials UK & Ireland 2015

SAN DIEGO – June 23, 2015 – Synteract, a full-service, international contract research organization (CRO), will participate in and present at the Outsourcing in Clinical Trials UK & Ireland 2015 conference in London from July 1-2. Synteract’s senior leadership team will be in attendance to discuss how the company can collaborate with small- to mid-sized pharma, biotech and device companies to help efficiently bring tomorrow’s treatments to the patients who need them.

Chief Medical Advisor Dr. Stephan de la Motte will present “What makes clinical trials in orphan indications so special?” at 9:30 a.m. on Thursday, July 2. There is growing demand for these types of trials due to US and EU orphan drug legislation that has made drug development for rare diseases more financially viable.

In his presentation, Dr. de la Motte will discuss:
• Defining rare diseases and orphan indications
• Evaluating the scientific limitations of clinical trials in orphan indications, including low sample size, improbability of running two studies, and lack of true surrogate variables
• Working with regulatory authorities toward the path to drug development and registration
• Discussing the unique characteristics of clinical trials with orphan treatments
• Conducting proactive, visible recruitment strategies for rare and orphan studies

Named one of the PharmaVOICE 100 Most Inspiring People in Life Sciences in 2014, Dr. de la Motte is renowned for his scientific and medical expertise and clinical trial knowledge of phase I, II and III studies. He’s written and presented extensively on the topic of orphan indications over the course of his career.

To set an appointment with the Synteract team in advance, contact Senior Director, Business Development Tony Dean at +44 (0)7771 846186.

For clinical research experts unable to attend the conference, Synteract will present at several other events this fall. The company will also host a free webinar on July 23 titled “The New EU Clinical Trials Regulation” in which attendees will hear an overview of new administrative provisions governing clinical trials in the European Union. For details on all events, please click here.

About Synteract                                                     
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies. Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, Synteract provides customized services collaboratively and cost effectively to provide “Tomorrow’s Treatments” to the patients who need them.

###

CONTACT:
Amanda Whitlock
amanda@clearpointagency.com
760-230-2424

x

Contact Synteract

Tell us how to stay in touch with you:

*Required